This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Why Homology Medicines (FIXX) Might Surprise This Earnings Season
by Zacks Equity Research
Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.